OncoMatch/Clinical Trials/NCT06192849
To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Is NCT06192849 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Furmonertinib for non small cell lung cancer.
Treatment: Furmonertinib — This is a phase II, prospective, multi-centre study. To assess the efficacy and safety of furmonertinib in patients with epidermal growth factor receptor 20ins mutation positive stage IB-IIIA Non-small Cell Lung Carcinoma, following complete tumour resection with or without adjuvant chemotherapy. The study plans to enroll 20 subjects, treating with furmonertinib 160mg/d, until disease recurrence, death or intolerability. The maximum duration of treatment is three years. The primary endpoint is DFS. The secondary endpoint include DFS rate , OS and the change of HRQoL. In addition, the peripheral blood ctDNA will be collected and analyzed in this study
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Biomarker criteria
Required: EGFR 20 insertion mutation
Patient with EGFR 20 insertion mutation diagnosed histologically or cytologically
Disease stage
Required: Stage IB, II, IIIA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anticancer therapy
Exception: excluding adjuvant platinum-based chemotherapy
Any prior anticancer therapy（excluding adjuvant platinum-based chemotherapy）
Lab requirements
Blood counts
Inadequate bone marrow reserve or organ function [excluded]
Kidney function
Inadequate bone marrow reserve or organ function [excluded]
Liver function
Inadequate bone marrow reserve or organ function [excluded]
Cardiac function
Mean resting corrected QT interval (QTc) >470 msec, obtained from 3 ECGs, using the screening clinic ECG Machine-derived QTc value; Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG; Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval
Inadequate bone marrow reserve or organ function; Mean resting corrected QT interval (QTc) >470 msec, obtained from 3 ECGs, using the screening clinic ECG Machine-derived QTc value; Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG; Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify